文献速递临床试验与 GCP基础与转化研究

含45S5生物活性玻璃颗粒的粘接系统用于磨牙-切牙矿化不全患牙及对生活质量影响:随机临床试验研究方案

Adhesive system containing Bioglass 45S5 particles in teeth affected by molar-incisor hypomineralization and quality of life impact: study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2025-05-09

本随机临床试验方案拟在6-12岁磨牙-切牙矿化不全(MIH)儿童的上颌或下颌第一恒磨牙上,比较含10% 45S5生物活性玻璃的实验性粘接剂与商品自酸蚀粘接系统(Clearfil SE Bond)的修复效果。采用复合树脂修复,以数字X线片、口内照片和环氧树脂复制品评估质量,按世界牙科联盟(FDI)标准在基线及1、3、6、12个月进行临床评价,并在3、6、12个月复测儿童感知问卷(CPQ8-10和CPQ11-14)评估生活质量影响。

要点

  • 研究对象为6-12岁MIH儿童的上颌或下颌第一恒磨牙,纳入牙体釉质破裂累及牙本质中三分之一且邻近至少两个面有矿化不全釉质、无龋坏及牙髓根周受累的患牙。
  • 分为对照组(Clearfil SE Bond Primer+Bond)和实验组(CF Primer+含10% 45S5生物活性玻璃的实验性Bond)。
  • 主要评价包括FDI标准临床评估(基线及1、3、6、12个月)和CPQ8-10、CPQ11-14生活质量问卷(3、6、12个月)。

核心结论

  • 本方案旨在评估含45S5生物活性玻璃的粘接系统用于MIH患牙修复治疗的效果,并评估治疗对生活质量的影响。

研究设计与样本

  • 随机临床试验研究方案,拟在6-12岁MIH儿童的上颌或下颌第一恒磨牙上进行修复治疗,分为对照组(商品自酸蚀粘接系统Clearfil SE Bond Primer+Bond)和实验组(CF Primer+含10% 45S5生物活性玻璃的实验性Bond),使用复合树脂修复。

主要发现

  • 45S5生物活性玻璃能够增强材料对骨和牙齿结构的作用,促进再矿化。
  • 研究结果可能有助于MIH患者的临床管理,因为敏感和受损牙齿的治疗具有挑战性,且在满足个体患者需求的同时实现长期修复成功较为困难。

关键数值与推荐

  • 纳入标准包括MIH患牙存在釉质萌出后破裂并累及牙本质中三分之一,邻近至少两个面有矿化不全釉质,无龋坏、牙髓或根周受累。
  • 治疗前儿童需完成儿童感知问卷8-10和11-14(CPQ8-10和CPQ11-14)。
  • 修复质量采用数字X线片(邻面及根尖片)、口内照片和环氧树脂复制品评估;临床评价使用世界牙科联盟(FDI)标准,在术后即刻(基线)及1、3、6、12个月进行;生活质量影响在3、6、12个月通过复测CPQ8-10和CPQ11-14评估。
  • 试验注册号为Rebec U1111-1259-1738,于2021年1月10日注册。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molar-incisor hypomineralization (MIH) is a systemic condition characterized by a qualitative defect in the dental enamel. It primarily affects the first permanent molars and is often associated with the permanent incisors. Resin restorations in MIH-affected teeth consistently show worse results than those in normal teeth because of the ultrastructure of hypomineralized enamel, which compromises adhesion. The incorporation of bioactive particles into adhesives is a promising option for inducing remineralization. This study protocol describes a randomized clinical trial evaluating restorative treatment using an adhesive system containing 45S5 bioactive glass for MIH-affected teeth. METHODS: Restorations will be performed on the upper or lower first permanent molars in children with MIH aged 6-12 years. The inclusion criteria will include MIH teeth with post-eruptive enamel fractures that compromise the middle third of the dentin, with at least two surfaces of hypomineralized enamel near the cavity, without caries, pulpal, or periradicular involvement. Before treatment, children will complete the Child Perceptions Questionnaire 8-10 and 11-14 (CPQ8-10 and CPQ11-14). The teeth will be divided into two groups: a control group (commercial self-etching adhesive system: Clearfil SE Bond (CF) Primer + Bond) and an experimental group (CF Primer + experimental Bond using 10% 45S5 bioglass [Bond 45S5 10%]). Restorations will be made using composite resin, and quality will be assessed using digital radiographs (interproximal and periapical), intraoral photographs, and epoxy resin replicas. Clinical evaluation of the restorations will be performed immediately following the procedure (baseline) and after 1, 3, 6, and 12 months using the World Dental Federation (FDI) criteria. The impact of the treatment on the quality of life will be assessed after 3, 6, and 12 months through the re-administration of CPQ8-10 and CPQ11-14. DISCUSSION: 45S5 bioactive glass is capable of enhancing the effect of materials on bone and dental structures, promoting remineralization. The results of this study may aid in the clinical management of patients with MIH, given the challenges of treating sensitive and compromised teeth and the difficulty in achieving long-term restorative success while addressing the individual patient needs. TRIAL REGISTRATION: Rebec, U1111-1259-1738. Registered on January 10, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. da Costa KNB, Veras NP, Carvalho CN, et al. Adhesive system containing Bioglass 45S5 particles in teeth affected by molar-incisor hypomineralization and quality of life impact: study protocol for a randomized clinical trial. Trials. 2025. PMID: 40346619. doi:10.1186/s13063-025-08853-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。